Carl Vahldieck – InmunoES

Complement C5 inhibition in generalized myasthenia gravis is associated with improved survival and increased cardiovascular risk

14 de May de 2026 by Carl Vahldieck

BackgroundComplement C5 inhibitors are effective disease-modifying therapies for acetylcholine receptor antibody-positive generalized myasthenia gravis (MG), but cardiovascular safety has not been evaluated as a dedicated outcome domain. With increasin…

Dysregulated complement activation during acute myocardial infarction leads to endothelial glycocalyx degradation and endothelial dysfunction via the C5a:C5a-Receptor1 axis

11 de July de 2024 by Carl Vahldieck

IntroductionComplement-mediated damage to the myocardium during acute myocardial infarction (AMI), particularly the late components of the terminal pathway (C5-convertase and C5b-9), have previously been characterized. Unfortunately, only few studies h…